Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.105 -0.025 (-0.80%)
Streaming Delayed Price Updated: 2:55 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today? ↗
Via Stocktwits
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug ↗
Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage. 
Via Stocktwits
News headline image
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026. 
Via Chartmill
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.